• About Us
  • Strategy
  • Our Team
  • Portfolio
  • News
  • Contact
  • Building Market-Leading Healthtech Companies

    About Us
    Header Pattern

    Sector Focus

    Medical Devices

    Tools & Diagnostics

    Digital Health

    Tech-Enabled Services

    Our Strategy

    Portfolio

    Leaders in Healthcare Technology Investing

    See All
    Ai cureCarti Heal Logo Website v3CogentixEndogastric solutionsKeystoneMedminderMemic Medical Logo BWNeuro Pace Logo Website 3Strata

    DEEP EXPERIENCE. SHARED COMMITMENT.

    "We take a private equity approach to a sector that’s traditionally been dominated by venture and early-stage growth firms. We'll work very closely with management to improve the operations of the business, update the product portfolio and revamp the commercial organization. We provide the support and resources our portfolio companies need to succeed.”

    Meet Our Team
    19
    active portfolio companies
    +
    1200
    employees worldwide
    3
    AP-II Investments to Date
    9
    successful exits

    news

    Oct 22, 2021

    Accelmed and H.I.G. BioHealth Co-Lead $52 Million Series B for Click Therapeutics

    Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has closed a $52 million upsized Series B financing

    Read More

    Sep 14, 2021

    Accelmed announces hiring of Katherine Relle as Vice President

    Accelmed Partners announced Katherine Relle has joined the firm as Vice President from J.P. Morgan’s Private Equity Group.

    Sep 01, 2021

    Keystone Dental acquires Osteon Medical, raises $25m led by Nantahala

    Accelmed Partners I portfolio company Keystone Dental Inc. announced the acquisition of Osteon Medical and the completion of a $25 million financing round led by Nantahala, with participation from Accelmed and Migdal Insurance.

    Aug 30, 2021

    CartiHeal to be acquired by Bioventus for $500 million

    Accelmed Ventures portfolio company CartiHeal is being acquired by Bioventus for $350 million in upfront consideration and up to $500 million including earn-outs.

    Contact Us

    Partner with Us

    Get in touch